Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

The UK list price of the weight loss drug could nearly triple, but which patients will bear the brunt of the internationally “aligned” cost? Kate Bowie reports In May the Trump administration demanded ...

The manufacturer of Ozempic (and other Semaglutide brands) faces over $2 billion in lawsuits filed by over 1,800 patients claiming blindness, stomach paralysis, and more.

A Shropshire GP has said many patients are worried about having to stop their weight loss journey as the cost of Mounjaro is ...

One of the harsh realities of the equities arena is that it’s open and entropic. In other words, exogenous factors could come ...

It comes after Mounjaro's manufacturer, Eli Lilly, announced it would be increasing the price of the GLP-1 jabs in the UK by ...

A doctor has explained how the body adjusts to the weight-loss drug Mounjaro during its first month of use. Weight loss drugs ...

Over the past year, Eli Lilly ($LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...